IO Biotech Inc. - חוב לטווח קצר של החברה IOBT

IO Biotech, Inc. (IOBT) focuses on assisting patients with terminal melanoma and severe tumors. The financial model relies on the creation of personalized vaccines, the costs of which are fully reimbursed by insurance companies. The current metric stands at 0.00. The firm is currently completing the final stage of testing for its innovative drug as it approaches full-scale sales. This price chart below illustrates the asset's price action amid preparations for commercialization.

For IO Biotech, Inc. (IOBT), which develops advanced cancer vaccines, short-term debt reflects loan obligations maturing within one year. This metric aggregates all current borrowings to determine the immediate pressure on liquidity. By analyzing the short-term debt trajectory, an investor assesses the company's ability to service its obligations without disrupting R&D. A decrease in this indicator confirms financial autonomy, ensuring the sustainability of the strategy to achieve leadership in combination therapy.